Literature DB >> 9765155

Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK.

T Bondeva1, L Pirola, G Bulgarelli-Leva, I Rubio, R Wetzker, M P Wymann.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) activate protein kinase PKB (also termed Akt), and PI3Kgamma activated by heterotrimeric guanosine triphosphate-binding protein can stimulate mitogen-activated protein kinase (MAPK). Exchange of a putative lipid substrate-binding site generated PI3Kgamma proteins with altered or aborted lipid but retained protein kinase activity. Transiently expressed, PI3Kgamma hybrids exhibited wortmannin-sensitive activation of MAPK, whereas a catalytically inactive PI3Kgamma did not. Membrane-targeted PI3Kgamma constitutively produced phosphatidylinositol 3,4, 3,4,5-trisphosphate and activated PKB but not MAPK. Moreover, stimulation of MAPK in response to lysophosphatidic acid was blocked by catalytically inactive PI3Kgamma but not by hybrid PI3Kgammas. Thus, two major signals emerge from PI3Kgamma: phosphoinositides that target PKB and protein phosphorylation that activates MAPK.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765155     DOI: 10.1126/science.282.5387.293

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  63 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.

Authors:  B Vanhaesebroeck; K Higashi; C Raven; M Welham; S Anderson; P Brennan; S G Ward; M D Waterfield
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

3.  Mechanism of the regulation of type IB phosphoinositide 3OH-kinase byG-protein betagamma subunits.

Authors:  Sonja Krugmann; Matthew A Cooper; Dudley H Williams; Phillip T Hawkins; Len R Stephens
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

4.  Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Authors:  C D Darr; A Mauser; S Kenney
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1, -2, -3 and -4.

Authors:  J H Wain; J A Kirby; S Ali
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

6.  Structural determinants of Ras-Raf interaction analyzed in live cells.

Authors:  Tzvetanka Bondeva; András Balla; Péter Várnai; Tamas Balla
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

7.  Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34.

Authors:  Simon Miller; Brandon Tavshanjian; Arkadiusz Oleksy; Olga Perisic; Benjamin T Houseman; Kevan M Shokat; Roger L Williams
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

8.  Distinguishing modes of eukaryotic gradient sensing.

Authors:  R Skupsky; W Losert; R J Nossal
Journal:  Biophys J       Date:  2005-08-05       Impact factor: 4.033

9.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.

Authors:  Sohye Kang; Adam Denley; Bart Vanhaesebroeck; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

10.  Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates.

Authors:  Mary P Horn; Sharmon M Knecht; Frances L Rushing; Julie Birdsong; C Parker Siddall; Charron M Johnson; Terri N Abraham; Amy Brown; Catherine B Volk; Kelly Gammon; Derron L Bishop; John L McKillip; Susan A McDowell
Journal:  J Pharmacol Exp Ther       Date:  2008-04-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.